Literature DB >> 30782997

Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal.

Marie Gladys Robert1,2, Francis Foguim Tsombeng1,2, Mathieu Gendrot1,2, Silman Diawara3, Marylin Madamet1,2,4, Mame Bou Kounta5, Khalifa Ababacar Wade5, Mansour Fall6, Mamadou Wague Gueye3, Nicolas Benoit1,2,4, Aminata Nakoulima7, Raymond Bercion8, Rémy Amalvict1,2,4, Bécaye Fall3, Boubacar Wade9, Bakary Diatta6,9, Bruno Pradines10,2,3,4.   

Abstract

Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. Neither the exonuclease E415G mutation nor the copy number variation of the plasmepsin II gene (Pfpm2), associated with piperaquine resistance in Cambodia, was detected in Senegalese parasites.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Plasmodium falciparumzzm321990; antimalarial drug; in vitrozzm321990; malaria; molecular marker; piperaquine; plasmepsin IIzzm321990; resistance

Year:  2019        PMID： 30782997      PMCID： PMC6496083          DOI： 10.1128/AAC.02445-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  45 in total

1.  Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.

Authors:  Sharon Wein; Marjorie Maynadier; Christophe Tran Van Ba; Rachel Cerdan; Suzanne Peyrottes; Laurent Fraisse; Henri Vial
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

2.  Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas.

Authors:  Hervé Bogreau; François Renaud; Housem Bouchiba; Patrick Durand; Serge-Brice Assi; Marie-Claire Henry; Eric Garnotel; Bruno Pradines; Thierry Fusai; Boubacar Wade; Eric Adehossi; Philippe Parola; Mohamed Ali Kamil; Odile Puijalon; Christophe Rogier
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

3.  Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.

Authors:  Patrick Tumwebaze; Melissa D Conrad; Andrew Walakira; Norbert LeClair; Oswald Byaruhanga; Christine Nakazibwe; Benjamin Kozak; Jessica Bloome; Jaffer Okiring; Abel Kakuru; Victor Bigira; James Kapisi; Jennifer Legac; Jiri Gut; Roland A Cooper; Moses R Kamya; Diane V Havlir; Grant Dorsey; Bryan Greenhouse; Samuel L Nsobya; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

4.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.

Authors:  Roberto Amato; Pharath Lim; Olivo Miotto; Chanaki Amaratunga; Dalin Dek; Richard D Pearson; Jacob Almagro-Garcia; Aaron T Neal; Sokunthea Sreng; Seila Suon; Eleanor Drury; Dushyanth Jyothi; Jim Stalker; Dominic P Kwiatkowski; Rick M Fairhurst
Journal:  Lancet Infect Dis       Date:  2016-11-03       Impact factor: 25.071

5.  Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.

Authors:  Rithea Leang; Walter R J Taylor; Denis Mey Bouth; Lijiang Song; Joel Tarning; Meng Chuor Char; Saorin Kim; Benoit Witkowski; Valentine Duru; Anais Domergue; Nimol Khim; Pascal Ringwald; Didier Menard
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

6.  Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.

Authors:  Bécaye Fall; Cheikhou Camara; Mansour Fall; Aminata Nakoulima; Pierre Dionne; Bakary Diatta; Yaya Diemé; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2015-02-06       Impact factor: 2.979

7.  Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand.

Authors:  Suwanna Chaorattanakawee; Chanthap Lon; Krisada Jongsakul; Jariyanart Gawee; Somethy Sok; Siratchana Sundrakes; Nareth Kong; Chatchadaporn Thamnurak; Soklyda Chann; Sorayut Chattrakarn; Chantida Praditpol; Nillawan Buathong; Nichapat Uthaimongkol; Philip Smith; Narongrid Sirisopana; Rekol Huy; Satharath Prom; Mark M Fukuda; Delia Bethell; Douglas S Walsh; Charlotte Lanteri; David Saunders
Journal:  Malar J       Date:  2016-10-21       Impact factor: 2.979

8.  Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

Authors: 
Journal:  Lancet       Date:  2018-03-29       Impact factor: 79.321

9.  Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.

Authors:  Mwaka A Kakolwa; Muhidin K Mahende; Deus S Ishengoma; Celine I Mandara; Billy Ngasala; Erasmus Kamugisha; Johannes B Kataraihya; Renata Mandike; Sigsbert Mkude; Frank Chacky; Ritha Njau; Zul Premji; Martha M Lemnge; Marian Warsame; Didier Menard; Abdunoor M Kabanywanyi
Journal:  Malar J       Date:  2018-10-17       Impact factor: 2.979

10.  Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone.

Authors:  Samuel J Smith; Anitta R Y Kamara; Foday Sahr; Mohamed Samai; Alpha S Swaray; Didier Menard; Marian Warsame
Journal:  Acta Trop       Date:  2018-06-19       Impact factor: 3.112
View more
  5 in total

1.  Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization.

Authors:  Nonlawat Boonyalai; Brian A Vesely; Chatchadaporn Thamnurak; Chantida Praditpol; Watcharintorn Fagnark; Kirakarn Kirativanich; Piyaporn Saingam; Chaiyaporn Chaisatit; Paphavee Lertsethtakarn; Panita Gosi; Worachet Kuntawunginn; Pattaraporn Vanachayangkul; Michele D Spring; Mark M Fukuda; Chanthap Lon; Philip L Smith; Norman C Waters; David L Saunders; Mariusz Wojnarski
Journal:  Malar J       Date:  2020-07-25       Impact factor: 2.979

2.  Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?

Authors:  Francis Foguim Tsombeng; Mathieu Gendrot; Marie Gladys Robert; Marylin Madamet; Bruno Pradines
Journal:  Malar J       Date:  2019-08-23       Impact factor: 2.979

3.  Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.

Authors:  Francis Tsombeng Foguim; Hervé Bogreau; Mathieu Gendrot; Joel Mosnier; Isabelle Fonta; Nicolas Benoit; Rémy Amalvict; Marylin Madamet; Sharon Wein; Bruno Pradines
Journal:  Malar J       Date:  2020-06-05       Impact factor: 2.979

4.  Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum.

Authors:  Mathieu Gendrot; Océane Delandre; Marie Gladys Robert; Francis Tsombeng Foguim; Nicolas Benoit; Rémy Amalvict; Isabelle Fonta; Joel Mosnier; Marylin Madamet; Bruno Pradines; On Behalf Of The French National Reference Centre For Imported Malaria Study Group
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-09

5.  A single point mutation in the Plasmodium falciparum 3'-5' exonuclease does not alter piperaquine susceptibility.

Authors:  Nonlawat Boonyalai; Kirakarn Kirativanich; Chatchadaporn Thamnurak; Chantida Praditpol; Brian A Vesely; Mariusz Wojnarski; John S Griesenbeck; Norman C Waters
Journal:  Malar J       Date:  2022-04-22       Impact factor: 3.469
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.